RCT: Comparison of Levetiracetam vs. Zonisamide vs. Lamotrigine for newly diagnosed focal epilepsy shows Lamotrigine should remain the first-line treatment option

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial – The Lancet

Commentary: Clinical trials assess best first-line drugs for epilepsy – University of Liverpool